TheraRadar
← Back
Data updated: Jul 17, 2026

ZUREX PHARMA

Pharma
Infectious DiseaseDermatology Execution: Excellent

ZUREX PHARMA is a pharmaceutical company focused on Infectious Disease, Dermatology. Key products include ZURAGARD.

2019
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

ZUREX PHARMA at a Glance

  • Strong track record with 92% execution quality across 9 trials
  • Fast trial execution (3 months median completion)

ZUREX PHARMA's Key Drugs

ZUREX PHARMA's core commercial portfolio centers on ZURAGARD, spanning Infectious Disease and Dermatology — its most strategically important drugs approved in the last 15 years.

ZURAGARD
Dermatology
Approved 2019

ZUREX PHARMA's Recent FDA Approvals

New NDA/BLA approvals for ZUREX PHARMA over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

ZUREX PHARMA's Therapeutic Areas

ZUREX PHARMA's approved drugs and pipeline span 2 therapeutic areas, led by Infectious Disease and Dermatology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Infectious Disease 54%
0 drugs Phase 3: 2 Phase 2: 2 Phase 1: 2
Dermatology 46%
0 drugs Phase 3: 3

ZUREX PHARMA's Top Competitors

ZUREX PHARMA's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and B BRAUN. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Pfizer big-pharma
Infectious Disease, Dermatology
Baxter specialty
Infectious Disease, Dermatology
B BRAUN specialty
Infectious Disease, Dermatology
BAUSCH AND LOMB INC other
Infectious Disease, Dermatology
KING PHARMS LLC big-pharma
Infectious Disease, Dermatology

ZUREX PHARMA Pipeline Snapshot

ZUREX PHARMA has 9 active clinical programs from ClinicalTrials.gov — 5 Phase 3, 2 Phase 2 and 2 Phase 1.

5
Phase 3
2
Phase 2
2
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • ZURAGARD leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Infectious Disease pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 5/5 completed
  • • Speed: 3 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges